Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer
This study was to evaluate the efficacy and safety of SHR-A1811 in patients with locally advanced unresectable or recurrent metastatic BTC with HER2 expression / amplification who failed first-line or second-line systemic treatment.
HER2 Expression / Amplification in Patients With Biliary Tract Cancer
DRUG: SHR-A1811
ORR evaluated by IRC according to RECIST v1.1 standard, About a year
DoR evaluated by IRC according to RECIST v1.1 standard, About a year|DCR evaluated by IRC according to RECIST v1.1 standard, About a year|PFS evaluated by IRC according to RECIST v1.1 standard, About a year|ORR evaluated by the researchers according to the RECIST v1.1 standard, About a year|DCR evaluated by the researchers according to the RECIST v1.1 standard, About a year|DoR evaluated by the researchers according to the RECIST v1.1 standard, About a year|PFS evaluated by the researchers according to the RECIST v1.1 standard, About a year|OS, About two year|AE, About a year|SAE, About a year
This study was to evaluate the efficacy and safety of SHR-A1811 in patients with locally advanced unresectable or recurrent metastatic BTC with HER2 expression / amplification who failed first-line or second-line systemic treatment.